Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation.
Patients with active DNA repair genes survive longer from breast cancer, independent of whether they received specific therapies.
HR repair axis positivity associated with reduced mortality risk in breast cancer (HR=0.508, 95% CI 0.411-0.627; I2=0%), independent of PARPi exposure; PARP1 mRNA as adverse prognostic marker remains inconclusive. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- systematic review and meta-analysis (18 studies, 13,641 patients) with TCGA validation
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Large meta-analysis clarifying prognostic value of HR repair axis and PARP1 in breast cancer with TCGA validation, relevant for PARPi patient selection in the context of expanding precision oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.